These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33666959)

  • 1. Peroral targeting of drug micro or nanocarriers to sites beyond the gastrointestinal tract.
    Zhang Z; Qi J; Lu Y; Wu W; Yuan H
    Med Res Rev; 2021 Jul; 41(4):2590-2598. PubMed ID: 33666959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral targeted drug delivery to post-gastrointestinal sites.
    Han R; He H; Lu Y; Lu H; Shen S; Wu W
    J Control Release; 2024 Jun; 370():256-276. PubMed ID: 38679163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarriers transport across the gastrointestinal barriers: The contribution to oral bioavailability via blood circulation and lymphatic pathway.
    Wang D; Jiang Q; Dong Z; Meng T; Hu F; Wang J; Yuan H
    Adv Drug Deliv Rev; 2023 Dec; 203():115130. PubMed ID: 37913890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on oral drug delivery
    Zhang Z; Lu Y; Qi J; Wu W
    Acta Pharm Sin B; 2021 Aug; 11(8):2449-2468. PubMed ID: 34522594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery.
    Kahraman E; Güngör S; Özsoy Y
    Ther Deliv; 2017 Nov; 8(11):967-985. PubMed ID: 29061106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
    Hunter AC; Elsom J; Wibroe PP; Moghimi SM
    Nanomedicine; 2012 Sep; 8 Suppl 1():S5-20. PubMed ID: 22846372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unlocking the potential of microfold cells for enhanced permeation of nanocarriers in oral drug delivery.
    Schreiner J; Brettner FEB; Gier S; Vogel-Kindgen S; Windbergs M
    Eur J Pharm Biopharm; 2024 Sep; 202():114408. PubMed ID: 39004319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
    Hunter AC; Elsom J; Wibroe PP; Moghimi SM
    Maturitas; 2012 Sep; 73(1):5-18. PubMed ID: 22709523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs.
    Ojer P; Iglesias T; Azqueta A; Irache JM; López de Cerain A
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):206-17. PubMed ID: 26493712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid lipid nanocarriers in drug delivery: characterization and design.
    Mu H; Holm R
    Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
    He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
    Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers.
    D'Addio SM; Baldassano S; Shi L; Cheung L; Adamson DH; Bruzek M; Anthony JE; Laskin DL; Sinko PJ; Prud'homme RK
    J Control Release; 2013 May; 168(1):41-9. PubMed ID: 23419950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances.
    Shreya AB; Raut SY; Managuli RS; Udupa N; Mutalik S
    AAPS PharmSciTech; 2018 Dec; 20(1):15. PubMed ID: 30564942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
    Nabi B; Rehman S; Baboota S; Ali J
    AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
    Managuli RS; Raut SY; Reddy MS; Mutalik S
    Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes.
    Silva AC; Santos D; Ferreira D; Lopes CM
    Curr Med Chem; 2012; 19(26):4495-510. PubMed ID: 22834821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications.
    Zhang Y; Wang Y; Li X; Nie D; Liu C; Gan Y
    J Control Release; 2022 Dec; 352():813-832. PubMed ID: 36368493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of oral targeted drug delivery: Gut immune to particulates?
    Ren Y; Wu W; Zhang X
    Acta Pharm Sin B; 2023 Jun; 13(6):2544-2558. PubMed ID: 37425061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red and NIR Light-Responsive Polymeric Nanocarriers for On-Demand Drug Delivery.
    He X; Yang X; Li D; Cao Z
    Curr Med Chem; 2020; 27(23):3877-3887. PubMed ID: 30767731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.